慢性疼痛静脉氯胺酮输注共识指南
该共识由美国区域麻醉与疼痛医学学会、美国疼痛医学学会及美国麻醉医师学会共同制定,针对慢性疼痛静脉氯胺酮输注的适应证、禁忌证、剂量、监测及疗效评估等形成推荐。证据支持氯胺酮用于慢性疼痛,但证据水平因疾病和剂量范围而异,多数研究样本小、对照不足。
要点
- 证据支持氯胺酮用于慢性疼痛,但证据水平因疾病和剂量范围而异。
- 多数疗效研究样本小、无对照或盲法不充分。
- 不良反应少,严重不良反应发生率与安慰剂相似,但高剂量和频繁输注风险更高。
核心结论
- 证据支持氯胺酮用于慢性疼痛,但证据水平因疾病和剂量范围而异。
研究设计与样本
- 2017年末文件提交至美国麻醉医师学会疼痛医学委员会及标准与实践参数委员会,之后进一步修改。
- 面板成员由委员会主席和两学会董事会基于评估临床试验的专业知识、既往研究经验及制定氯胺酮方案和治疗患者的临床经验选定。
- 每个问题由3至5名面板成员组成的模块组负责处理,初步共识达成后发送全体面板进一步修订。
- 除共识指南外,还进行了全面的叙述性综述,作为指南依据的一部分。
主要发现
- 指南涵盖适应证、禁忌证、剂量反应关系或最低/治疗剂量范围证据、口服氯胺酮或其他NMDA受体拮抗剂作为输注后后续治疗选择、输注前检测要求、实施和监测所需的设置与人员、预防性和救援药物处理不良反应、以及阳性治疗反应的定义。
- 专家组在所有问题上达成共识。
- 评估氯胺酮疗效的研究大多样本小、无对照,且未设盲或盲法无效。
- 不良反应少,多数研究中严重不良反应发生率与安慰剂相似,较高剂量和更频繁输注与更大风险相关。
临床怎么用
- 临床可依据该共识指南对慢性疼痛患者使用静脉氯胺酮输注,但需注意证据水平因疾病和剂量范围而异。
- 实施输注时应考虑指南中关于设置、人员、监测及预防性和救援药物使用的推荐。
- 应关注较高剂量和更频繁输注带来的更大风险。
局限性
- 大多数评估氯胺酮疗效的研究样本小、无对照,且未设盲或盲法无效。
- 需要更大规模的研究,评估更广泛的疾病种类,以更好地量化疗效、改善患者选择、优化治疗剂量范围、确定非静脉氯胺酮替代品的有效性,并加深对重复治疗长期风险的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past 2 decades, the use of intravenous ketamine infusions as a treatment for chronic pain has increased dramatically, with wide variation in patient selection, dosing, and monitoring. This has led to a chorus of calls from various sources for the development of consensus guidelines. METHODS: In November 2016, the charge for developing consensus guidelines was approved by the boards of directors of the American Society of Regional Anesthesia and Pain Medicine and, shortly thereafter, the American Academy of Pain Medicine. In late 2017, the completed document was sent to the American Society of Anesthesiologists' Committees on Pain Medicine and Standards and Practice Parameters, after which additional modifications were made. Panel members were selected by the committee chair and both boards of directors based on their expertise in evaluating clinical trials, past research experience, and clinical experience in developing protocols and treating patients with ketamine. Questions were developed and refined by the committee, and the groups responsible for addressing each question consisted of modules composed of 3 to 5 panel members in addition to the committee chair. Once a preliminary consensus was achieved, sections were sent to the entire panel, and further revisions were made. In addition to consensus guidelines, a comprehensive narrative review was performed, which formed part of the basis for guidelines. RESULTS: Guidelines were prepared for the following areas: indications; contraindications; whether there was evidence for a dose-response relationship, or a minimum or therapeutic dose range; whether oral ketamine or another N-methyl-D-aspartate receptor antagonist was a reasonable treatment option as a follow-up to infusions; preinfusion testing requirements; settings and personnel necessary to administer and monitor treatment; the use of preemptive and rescue medications to address adverse effects; and what constitutes a positive treatment response. The group was able to reach consensus on all questions. CONCLUSIONS: Evidence supports the use of ketamine for chronic pain, but the level of evidence varies by condition and dose range. Most studies evaluating the efficacy of ketamine were small and uncontrolled and were either unblinded or ineffectively blinded. Adverse effects were few and the rate of serious adverse effects was similar to placebo in most studies, with higher dosages and more frequent infusions associated with greater risks. Larger studies, evaluating a wider variety of conditions, are needed to better quantify efficacy, improve patient selection, refine the therapeutic dose range, determine the effectiveness of nonintravenous ketamine alternatives, and develop a greater understanding of the long-term risks of repeated treatments.
引用
- Cohen SP, Bhatia A, Buvanendran A, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018. PMID: 29870458. doi:10.1097/AAP.0000000000000808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。